Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
<h4>Purpose</h4>Phase 1 trials play a crucial role in oncology by translating laboratory science into efficient therapies. Molecular targeted agents (MTA) differ from traditional cytotoxics in terms of both efficacy and toxicity profiles. Recent reports suggest that higher doses are not...
Guardado en:
Autores principales: | Charles Ferte, Jean-Charles Soria, Nicolas Penel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a2a81cdc79344aebd66a927e68dc8c6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Predictive value of clinical judgment of tumour progression in phase II trials.
por: Nuria Kotecki, et al.
Publicado: (2012) -
Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov
por: Julia Lai‐Kwon, et al.
Publicado: (2021) - Contemporary Oncology / Wspolczesna Onkologia
-
Trial-level factors affecting accrual and completion of oncology clinical trials: A systematic review
por: Cherie L. Hauck, et al.
Publicado: (2021) -
Contemporary clinical trials
Publicado: (2005)